DEM BioPharma Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $70M

  • Investors
  • 9

DEM BioPharma General Information

Description

Developer of an immunotherapeutics platform designed to pioneer the next generation of macrophage immunotherapies. The company's platform researches the generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting signals on cancer cells and macrophages, enabling healthcare researchers with a treatment that removes cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 730 Main Street
  • 5th Floor
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 730 Main Street
  • 5th Floor
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DEM BioPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 23-Jun-2022 $70M Completed Generating Revenue
1. Seed Round Completed Startup
To view DEM BioPharma’s complete valuation and funding history, request access »

DEM BioPharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view DEM BioPharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

DEM BioPharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immunotherapeutics platform designed to pioneer the next generation of macrophage immunotherapies. The c
Drug Discovery
Cambridge, MA
20 As of 2026

Oslo, Norway
 

Emeryville, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DEM BioPharma Competitors (91)

One of DEM BioPharma’s 91 competitors is Zelluna, a Formerly VC-backed company based in Oslo, Norway.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zelluna Formerly VC-backed Oslo, Norway
Eureka Therapeutics Venture Capital-Backed Emeryville, CA
Navrogen Venture Capital-Backed Cheyney, PA
Dendreon Formerly VC-backed Seal Beach, CA
Carina Biotech Venture Capital-Backed Mawson Lakes, Australia
You’re viewing 5 of 91 competitors. Get the full list »

DEM BioPharma Patents

DEM BioPharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026112624-A2 Anti-smagp antibodies Pending 25-Nov-2024
WO-2026112624-A3 Anti-smagp antibodies Pending 25-Nov-2024
WO-2025194014-A1 Hetero aryl modulators of apmap and uses thereof Pending 15-Mar-2024
WO-2025194015-A1 Heteroaryl modulators of gpr84 and uses thereof Pending 15-Mar-2024
WO-2024258897-A1 Alkoxypyridinyl and related compounds and their use in therapy Inactive 13-Jun-2023 C07D213/69
To view DEM BioPharma’s complete patent history, request access »

DEM BioPharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DEM BioPharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
Alta Partners Venture Capital Minority
Astellas Venture Management Corporate Venture Capital Minority
DC Investment Partners Venture Capital Minority
Emerson Collective Impact Investing Minority
You’re viewing 5 of 9 investors. Get the full list »

DEM BioPharma FAQs

  • When was DEM BioPharma founded?

    DEM BioPharma was founded in 2022.

  • Where is DEM BioPharma headquartered?

    DEM BioPharma is headquartered in Cambridge, MA.

  • What is the size of DEM BioPharma?

    DEM BioPharma has 20 total employees.

  • What industry is DEM BioPharma in?

    DEM BioPharma’s primary industry is Drug Discovery.

  • Is DEM BioPharma a private or public company?

    DEM BioPharma is a Private company.

  • What is the current valuation of DEM BioPharma?

    The current valuation of DEM BioPharma is .

  • What is DEM BioPharma’s current revenue?

    The current revenue for DEM BioPharma is .

  • How much funding has DEM BioPharma raised over time?

    DEM BioPharma has raised $95M.

  • Who are DEM BioPharma’s investors?

    Alexandria Venture Investments, Alta Partners, Astellas Venture Management, DC Investment Partners, and Emerson Collective are 5 of 9 investors who have invested in DEM BioPharma.

  • Who are DEM BioPharma’s competitors?

    Zelluna, Eureka Therapeutics, Navrogen, Dendreon, and Carina Biotech are some of the 91 competitors of DEM BioPharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process